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MUC1, a transmembrane mucin, is a key modulator of sev-
eral signaling pathways that affect oncogenesis, motility, and
cell morphology. The interaction of MUC1 cytoplasmic tail
(MUC1CT) with signal transducers and its nuclear transloca-
tion and subsequent biological responses are believed to be
regulated by phosphorylation status, but the precise mecha-
nisms by which this occurs remain poorly defined. We
detected a novel association between the Met receptor tyro-
sine kinase and theMUC1CT.Met catalyzed phosphorylation
of tyrosine at YHPM in the MUC1CT. Stimulation of
S2-013.MUC1F pancreatic cancer cells with hepatocyte
growth factor facilitated nuclear localization of MUC1CT, as
determined by real time confocal imaging analysis. MUC1
overexpression also facilitated faster turnover of Met. Phos-
phorylation of MUC1CT by Met enhanced its interaction
with p53, which led to suppression of AP1 transcription fac-
tor activity through interactions at theMMP1 promoter, ulti-
mately leading to reduced transcription of MMP1. This cor-
related with a decrease in hepatocyte growth factor-induced
invasiveness when MUC1 was overexpressed. The results
demonstrate that MUC1modulates Met-mediated oncogenic
signaling in cancer.
Met, a receptor tyrosine kinase of the semaphorin family that
regulates cell growth, invasion, and cell survival, is a het-
erodimericmolecule consisting of a 50-kDa extracellular sub-
unit and a 145-kDa transmembrane  subunit (1). The cyto-
plasmic tail of Met contains a kinase domain and a C-terminal
docking site, which recruits adaptor proteins (2). These inter-
actions aremodulated byHGF,2 a ligand forMet that stimulates
phosphorylation at different residues of Met and on other sub-
strates. Deregulated activation or overexpression of Met elicits
tumorigenic and metastatic effects and has been reported in
several cancers, including pancreatic adenocarcinoma (3–5).
HGF stimulation also induces degradation of Met and termi-
nates Met signaling, thus bringing cells back to homeostasis.
Human MUC1, a type I transmembrane protein normally
expressed on the apical surface of ductal epithelia, is overex-
pressed and aberrantly glycosylated in several cancers, includ-
ing pancreatic adenocarcinoma (6, 7).MUC1 is synthesized as a
single polypeptide chain but exists on the cell surface as a het-
erodimer. Co-translational proteolytic cleavage of the full-
length protein results in two associated fragments as follows: a
large extracellular polypeptide containing the tandem repeat
domain that can be released from the cell surface; and a
polypeptide consisting of the short extracellular region, the
transmembrane domain, and the cytoplasmic tail that exists as
an integral membrane protein (8, 9).
The cytoplasmic tail ofMUC1 (MUC1CT) containsmultiple
serine, threonine, and tyrosine residues, which are phosphoryl-
ated and involved in different signaling cascades in response to
changing cell surface conditions, including spatial reorganiza-
tion or stimulation with growth factors and cytokines (8).
Changes in the phosphorylation status of MUC1CT are
believed to modulate its affinity for mediators of signal trans-
duction, including -catenin, p53, and Grb2-SOS.
The processes that regulate phosphorylation of the
MUC1CT and the specific kinases that catalyze these reactions
are now being elucidated. The MUC1CT is a substrate for
GSK3, c-Src, EGFR, and platelet-derived growth factor recep-
tor- (10–13). Activated EGFR is reported to phosphorylate
the MUC1CT on tyrosine at a YEKV motif that functions as a
binding site for the c-Src Src homology 2 domain (12). EGFR-
mediated phosphorylation of MUC1CT induces binding of
MUC1CT to c-Src and enhances the binding affinity of
MUC1CT to -catenin. Interactions of MUC1CT with -cate-
nin are diminished by GSK3--mediated phosphorylation (12).
MUC1CT is translocated to the nucleus in association with
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-catenin, where it may influence the activity of the latter as a
transcriptional co-activator (12, 16). Nuclear translocation of
MUC1CT is mediated by its interaction with importin  and
nucleoporin Nup62 (17).
The in vivo phosphorylation status of MUC1CT and the
kinases that act on it in pancreatic cancer have not been well
characterized.We present evidence that theMet receptor tyro-
sine kinase interacts withMUC1 in pancreatic cancer cells, and
catalyzes phosphorylation of theMUC1CT in response to stim-
ulation byHGF.Overexpression ofMUC1 in pancreatic adeno-
carcinoma cells down-regulated conventional Met-mediated
signaling and inhibited motility and invasion. HGF stimulation
facilitated interaction of MUC1CT with p53, enabled p53-me-
diated suppression of AP1 transcriptional activity, and
decreasedMMP1 expression.We conclude that Met-mediated
phosphorylation of MUC1 modulates signaling related to
motility and invasion in pancreatic cancer.
EXPERIMENTAL PROCEDURES
Cell Culture—Panc-1 was obtained from the American Type
Culture Collection (Manassas, VA). S2-013 is a cloned subline
of a human pancreatic tumor cell line (SUIT-2) derived from a
liver metastasis (18). HPAF2 pancreatic tumor cells have been
described previously (19, 20). FLAG epitope-tagged MUC1
(MUC1F) transfectants of the S2-013 cell line (S2-
013.MUC1F), Panc1 cell line (Panc1.MUC1F), and cytosolic
tail-deleted MUC1 transfectants of the S2-013 cell line (S2-
013.CT3), and Panc1 (Panc1.CT3) were cultured as described
previously (21). MDA-MB-435 cells, previously described as
breast cancer cells but recently reported to be of melanoma
origin (22, 23), were stably transducedwith pLNCX.1 retroviral
vectors expressing wild type MUC1 or empty vector neo con-
trols, as described previously (24), to produce MDA-MB-
435.MUC1 and MDA-MB-435.neo, respectively. HPAF2 cells
were maintained in Eagle’s minimal essential medium (Invitro-
gen) supplemented with 10% heat-inactivated fetal bovine
serum, nonessential amino acids, sodiumpyruvate, and penicil-
lin/streptomycin under similar conditions.
Immunoblotting and Immunoprecipitation—Cell lysate pro-
teins were resolved on 10 or 14%NOVEXTris-glycine denatur-
ing polyacrylamide gels (Invitrogen) in a 1 SDS-PAGE buffer
(1 g/liter SDS, 3 g/liter Tris base, and 14.4 g/liter glycine).
Immunoblotting and immunoprecipitationswere performed as
described previously (14).
Biotinylation Assay—Cells serum-starved for 24 h were sur-
face-biotinylated with EZ-link Sulfo-NHS-SS-Biotin (Pierce)
on ice followed by washing and quenching of free biotin, and
then incubated at 37 °C in the presence or absence of 100 ng/ml
HGF (100 ng/ml, PeproTech, Rocky Hill, NJ) for 2 h. Following
the 2-h incubation, cell monolayers were glutathione-stripped
as described by Graeve et al. (25). Cells were incubated in two
20-min washes of glutathione solution (60 mM glutathione,
0.083MNaCl, with 0.083MNaCl, and 1%bovine serumalbumin
added before use) at 0 °C to remove the cell surface biotin
groups. The remaining biotinylated proteins, whichwere endo-
cytosed prior to biotin stripping, were recovered from the RIPA
cell lysates by incubation with neutravidin beads (Pierce).
In Vitro Kinase Assay—1 g of peptides in 10 l of reaction
buffer (Met reaction buffer: 40mMMOPS, pH7.5, 1mMEGTA)
were incubated at 37 °C for 30 min along with 10 Ci of
[-32P]ATP and 500 ng of active human recombinant Met
(Upstate Cell Signaling Solutions, Lake Placid, NY). The reac-
tion was stopped by boiling the samples in reducing SDS-sam-
ple buffer. Samples were resolved on 16% Tricine gel. The gel
was dried and analyzed by PhosphorImager analysis.
Metabolic Labeling of Cells and Radioimmunoprecipitation
Analysis—Metabolic labeling was performed as described pre-
viously (13). Briefly, HPAF2 cells were serum-starved for 24 h
and incubated in phosphate-free minimum essential medium
at 37 °C for 2 h prior to labeling with 2mCi/ml [32P]orthophos-
phate (ICN, Irvine, CA) for 2 h in the presence or absence of
100 ng/ml HGF. Whole cell lysates were prepared with ice-
cold radioimmunoprecipitation assay buffer. Radiolabeled
MUC1CT was immunoprecipitated by incubation with mAb
CT2 (mAb against MUC1CT) and resolved by SDS-PAGE on
a 14% gel.
Tandem MS Analysis of MUC1CT and Its Association
Partners—Immunoprecipitated MUC1CT from cell lysates or
in vitro phosphorylated MUC1CT peptides were resolved on
14% NOVEX Tris-glycine denaturing polyacrylamide gels
(Invitrogen), silver-stained, and then individual bands were
excised and trypsin-digested. Eluted peptides were analyzed
using a Q-TOF Ultima tandem mass spectrometer (Micro-
mass/Waters) with electrospray ionization as described previ-
ously (13).
Cell Migration and Invasion Assays—In vitro invasive poten-
tial of cells with and without HGF stimulation were assayed
using the Biocoatmigration orMatrigel invasion chambers (BD
Biosciences). S2-013.MUC1F, S2-013.CT3, and S2-013.Neo
cells (5 104) were seeded onto the upper chamber, which also
had a coating of Matrigel in the invasion chambers. The lower
chamber contained Dulbecco’s modified Eagle’s medium with
or without 100 ng/ml HGF. The chambers were cultured at
37 °C for 24 h in a CO2 incubator. Cells on the upper portion of
the membrane were wiped off with a cotton-tipped swab, and
cells on the bottom of this membrane were fixed and stained
with Diff-Quick staining kit (Allegiance) and observed by light
microscopy. The numbers of invading cells were counted in five
randomly selected observation fields per membrane at 200
magnification.
Plasmids, Transient Transfections, and Luciferase Assays—
MMP-1 luciferase reporter, wild type or mutated at the first
ETS site 388/385 (GGAT to AAAT), AP-1-binding site (370 to
368 from GTC to TGG), or the second ETS site 348/345
(GGAA to AAAA) were a kind gift from Dr. Ralf Janknecht
(Mayo Clinic, Rochester,MN) (26). AnAP1-responsive lucifer-
ase plasmid was obtained from Promega. PGL2 basic was used
as a control plasmid for transfection in luciferase studies. A dual
luciferase reporter assay (Promega) was used to detect pro-
moter activity in this study. A synthetic Renilla luciferase
reporter plasmid pRL-SV40 (Promega)was used as a control for
transfection efficiency. 10,000 cells/well were seeded into a
48-well plate and grown to60% confluence and then serum-
starved for 24 h and transfected using Lipofectamine 2000
Phosphorylation ofMUC1 byMet
26986 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 40•OCTOBER 3, 2008
 
 
(Invitrogen), with andwithout 100ng/mlHGF, and cultured for
another 24 h.The cellswere thenwashed twicewith phosphate-
buffered saline and harvestedwith 200l of Passive Lysis buffer
(Promega) and assayed for the luciferase activities. Each exper-
iment was performed three times in triplicate.
Chromatin Immunoprecipitation (ChIP) Assays—5.0  107
S2-013MUC1F cells were prepared for ChIP assays by cross-
linking for 30 min with 50 mM (10-fold molar excess) dimethyl
3,3-dithiobispropionimidate2 HCl (Pierce), followed by 10
min of cross-linking with 1% formaldehyde. The cross-linkers
were quenched with 125 mM glycine in phosphate-buffered
saline. The cells were scraped and sonicated to an average of
500 bp to prepare the chromatin as per the Affymetrix ChIP
protocol, which was subjected to immunoprecipitation with
either CT2 or IgG control. The immunoprecipitants were
washed and eluted as suggested by the protocol, and 3.0 l of
the eluted product was subjected to real time PCR using primer
sets for pGUSB (Superarray Bioscience Corp., Frederick,
MD), pMMP1 (forward, TGGCAGAGTGTGTCTCCTTCGC;
reverse, TCGAAGGTAAGTGAT-
GGCTTCC), or a control region 1.5
kb upstream of pMMP1 (forward,
TGCCTAGCACCAAGGAGCGA-
AGA; reverse, CGGAGTATGAG-
ATAACTCCCC) as described in
the Superarray protocol.
Statististical Analysis—Results
are expressed as mean S.E. of 3–5
independent experiments, each
treatment performed in triplicate.
Statistical analysis was performed
using the SPSS or GraphPad Prism
statistical software. Student’s t test
was used when appropriate. p 
0.05 was considered significant.
RESULTS
MUC1CT Interacts with Met—
Proteomics techniques were used to
identify proteins that co-immuno-
precipitated with MUC1 from
S2-013 pancreatic adenocarcinoma
cells, a moderately differentiated
human pancreatic tumor cell line
known to express O-glycosylated
mucin-like proteins, including low
levels of endogenous MUC1 (18). A
cDNA construct encoding a FLAG
epitope-tagged form of MUC1 (7)
was overexpressed in the these cells
(S2-013.MUC1F). Immunoprecipi-
tations with the CT2 antibody,
which binds to MUC1CT, were
resolved onTris-glycine SDS-PAGE
and silver-stained (supplemental
Fig. 1). Bands representing specific
proteins that co-immunoprecipi-
tated with MUC1 and were absent
from isotype control lanes were excised from the gel and sub-
jected to in-gel trypsin digestion and MS/MS analysis for pro-
tein identification. A fragment corresponding to the cytoplas-
mic tail of Met, FTVKVADFGLAR, was identified by this
approach (Fig. 1A).
We performed reciprocal co-immunoprecipitations of
MUC1 and Met from cell lysates of three human pancreatic
adenocarcinoma cell lines as follows: Panc1.MUC1F (a poorly
differentiated cell line overexpressing a FLAG-tagged MUC1
construct); S2-013.MUC1F; andHPAF2 (a highly differentiated
cell line with high endogenous levels of MUC1). Immunopre-
cipitations utilizing anti-cytoplasmic tail antibodies for both
molecules (Fig. 1B) were resolved on 10% SDS-PAGE to facili-
tate separation of pre-Met (unprocessed form) and Met and
Western blotted, and the membranes were probed with
HMFG-2 (a monoclonal antibody against the tandem repeat
region of MUC1) or an antibody against the Met cytoplasmic
tail. The immunoblotting results revealed consistent interac-
tions between MUC1 and Met in S2-013.MUC1F and HPAF2
FIGURE 1. Interaction of MUC1withMet. A, identification of Met as an interaction partner for MUC1 bymass
spectrometry. MUC1 was immunoprecipitated from S2-013.MUC1F and Panc1.MUC1F cells by mAb CT2 and
resolved on SDS-PAGE. The gel was silver-stained, and specific bands not observed in IgG control lanes were
excised and subjected to trypsin digestion followed by liquid chromatography-electrospray ionization-mass
spectrometric analysis. This analysis identified a tryptic fragment of Met indicated in the illustration. B, inter-
action of MUC1 and Met was confirmed by reciprocal co-immunoprecipitation. MUC1 was immunoprecipi-
tated (IP) from Panc1.MUC1F, S2-013.MUC1F, and HPAF2 pancreatic adenocarcinoma cells and immuno-
blotted (IB) for Met by using a polyclonal Ab for the cytoplasmic tail of Met. A reciprocal immunoprecipitation
of Met and immunoblotting with HMFG2 mAb raised against the tandem repeat region of MUC1 was also
performed (right panel).
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cells, and aweaker interactionwas observed for Panc-1.MUC1F
cells. Although the reason for the weaker interaction between
MUC1 and Met in Panc1.MUC1F cells is not definitively
known at this time, it is known that Panc1 is a poorly differen-
tiated pancreatic cancer cell line (27) that attaches core 1 type
short oligosaccharides (e.g. sialyl-Tn and sialyl-T) to MUC1
because of a lack of expression of core 2 GlcNAc transferase
activity (28). In contrast, S2-013 and HPAF2 are moderately
andwell differentiated pancreatic cancer cell lines, respectively,
that attach to MUC1 extended oligosaccharides such as sialyl
Lewis A (7) and sialyl Lewis C. This raises the possibility that
glycosylation of MUC1 influences its ability to interact with
Met. Both pre-Met andMetwere found to interact withMUC1.
MUC1 Facilitates Faster Turnover of Met—Because MUC1
and Met were in complex, we sought to determine whether
overexpression of MUC1 modulates stability of Met by
performing cell surface biotinylation experiments (25).
S2-013.MUC1F and S2-013.Neo cells were serum-starved for
24 h and then surface-biotinylated with a cell-impermeable
biotinylation reagent. The surface-biotinylated cells were stim-
ulated with HGF (100 ng/ml) for 0, 15, 60, or 120min. The cells
were glutathione-stripped to remove biotin from the nonendo-
cytosed cell surface proteins, thus specifically biotin-labeling
proteins that were endocytosed.
Ammonium chloride was used to
block lysosomal degradation of
endocytosed proteins. Proteins
from whole cell lysates were immu-
noprecipitated by using Neutravi-
din beads and subsequently immu-
noblotted forMet. HGF stimulation
caused a significant reduction in
total levels of Met protein in a tem-
poral manner in S2-013.MUC1F
cells (Fig. 2A). However, steady
state levels of Met were com-
paratively stable in S2-013.Neo
cells (which do not overexpress
MUC1), suggesting that MUC1
overexpression facilitated faster
turnover of Met during stimula-
tion with HGF. The increased
turnover of Met in S2-013.MUC1F
cells following HGF stimulation
was also associated with reduced
binding to Gab1, as demonstrated
by immunoprecipitation followed
by immunoblotting (Fig. 2B).
However, the interactions of
Met with Gab1 were higher in
S2-013.MUC1F cells under serum-
starved steady state conditions, as
compared with the S2-013.Neo
cells.
In Vitro Phosphorylation of
MUC1CT byMet—We investigated
whether Met phosphorylated the
MUC1CT by performing in vitro
kinase assays with a 66-merMUC1CT peptide (MUC1CT-p66,
representing the C-terminal 66 residues of 72-residue-long
MUC1CT) and recombinant active human Met kinase, in the
presence of [-32P]ATP. Autoradiograms from 32P-labeled in
vitro kinase reactions showed phosphorylation of MUC1CT-
p66 in the presence of Met (Fig. 3A, 3rd lane). No phosphoryl-
ationwas observed in the absence of peptide (Fig. 3A, 2nd lane),
or kinase (1st lane). Parallel reactions were applied to SDS-
PAGE followed by silver staining (Fig. 3A, bottom panel). Bands
corresponding to the MUC1CT peptide were digested with
trypsin and sequenced by tandem mass spectrometry. The
mass spectrometric analysis of MUC1CT revealed phospho-
rylation at tyrosine at the YHPM motif (or Tyr-1203, NCBI
accession number P15941; Fig. 3B). Furthermore, MUC1CT
peptide synthetically pre-phosphorylated at tyrosine in the
YHPM motif (MUC1CT-p66-pYHPM) was not phosphoryl-
ated by Met (Fig. 3A).
Increased MUC1CT Phosphorylation by HGF Stimulation of
Pancreatic Adenocarcinoma Cells—To investigate the in vivo
phosphorylation of MUC1CT by Met in pancreatic adeno-
carcinoma cells, HPAF2 cells were serum-starved for 24 h
followed by 2 h of incubation with 100 ng/ml recombinant
human HGF, an activating ligand for Met, in the presence of
FIGURE2.MUC1promotesendocytosis, lysosomaldegradation, and reducedsignalingofMet.A,effect of
MUC1 overexpression on Met endocytosis was determined in S2-013.MUC1F or S2-013.neo cells. Serum-
starved cells were surface-biotinylated on ice and then incubated at 37 °C for 2 h in the absence (serum-free or
SF) orpresenceofHGF (H) to allowendocytosis. Surface-biotinylatedproteins fromRIPA lysateswere recovered
on neutravidin beads and analyzed by SDS-PAGE, followed by Western blotting with a polyclonal Ab against
Met. 1st 3 lanes indicate the total levels of surface-biotinylatedMet after 2hof incubation at 0, 37, or 37 °C in the
presence of HGF and ammonium chloride, and 4th to 6th lanes represent the levels of endocytosed Met
(detected by glutathione stripping or GS) under serum-free conditions or HGF stimulation with and without
ammonium chloride. B, effect of HGF stimulation on Met signaling. S2-013.MUC1F or S2-013.neo cells were
stimulatedwith HGF for different times. Lysates were immunoprecipitatedwithMet cytoplasmic tail Ab or IgG
control. The immunoprecipitants were resolved on SDS-PAGE and immunoblotted (IB) with Abs against Gab1
or Met.
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[32P]orthophosphate. MUC1 was immunoprecipitated from
cell lysates with CT2 mAb and separated by SDS-PAGE, and
proteins were transferred onto a polyvinylidene difluoride
membrane, which was then subjected to autoradiography.
Cell lysates from unstimulated cells and lysates immunopre-
cipitated with an isotype identical Ab were used as controls.
A duplicate gel was immunoblotted with CT2 antibody to
identify the MUC1CT bands. Autoradiography revealed that
in vivo labeling of HPAF2 cells with [32P]orthophosphate
following stimulation with HGF induced a significant
increase in phosphorylation of MUC1CT, as compared with
unstimulated cells (Fig. 3C).
FIGURE 3.Metmediates phosphorylation and nuclear localization ofMUC1CT. A, recombinant activeMet kinase phosphorylatedMUC1CT-p66. MUC1CT-
p66 or MUC1CTp66-pYHPM peptides were incubated with Met kinase in the presence of [-32P]ATP. The reaction mixtures were resolved on SDS-PAGE
followedby autoradiographyor thegelwas stainedwithCoomassie Blue.B,MS/MS spectra of trypsinizedphospho-MUC1CT-p66 from in vitro kinase reactions.
MS/MS spectra of DTYHPMSEYPTYHTHGR peptide from Met-phosphorylated MUC1CT-p66 indicates phosphorylation of Y1. 32P labeling of HPAF2 cells was
performedunderHGFstimulation (C). HPAF2cellswere labeledwith [32P]orthophosphate (250Ci/ml) in thepresence (3rd lane) or absence (1st lane) of human
recombinant HGF (100 ng/ml), lysed in RIPA buffer, immunoprecipitated (IP) with mAb CT2, and subjected to autoradiography or immunoblotting with mAb
CT2. Immunoprecipitation with a nonspecific mAb was used as an IP control (2nd lane). Nuclear (N) and cytoplasmic (C) localization of MUC1CT from
S2-013.MUC1F cells (D) and HPAF2 cells (E) phosphorylated at tyrosine at the YHPM site were determined by Western blotting with phosphorylation site-
specific antibody. The polyvinylidene difluoridemembranewas reprobedwith antibodies against H2B and-actin as controls for protein loading. F, left panel,
S2-013.MUC1.CT-EYFP cells expressingMUC1with C-terminally tagged EYFPwere utilized for real time laser scanning confocalmicroscopy. The first two scans
were taken under serum-starved conditions, and HGF (100 ng/ml) was added to the culture disk right after the second scan, and successive scans were taken
for 15 min, every 10 s at 37 °C at 100 magnification. After the first 15 min, the rest of the scans were performed every 2.5 min for a total period of 4 h.
Representative real time confocal scans of a cluster of cells and a single cell are presented here. G, S2-013.MUC1F or S2-013.MUC1FHPM cells were serum-
starved for 24h, stimulatedwithHGF for 15min, or left unstimulated, fixed, andpermeabilizedbefore incubationwithmAbCT2 and thenuclear dyepropidium
iodide. The mAb CT2 (anti-MUC1CT) was visualized as blue (right panel) and detected by using a Cy5-conjugated secondary antibody, and nuclei were
visualized in red.White arrows indicate localization of MUC1CT outside the nucleus.
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HGF Stimulation Causes Nuclear Localization of MUC1CT
Phosphorylated at Tyrosine in the YHPMMotif—A rabbit poly-
clonal antibody specific for phosphorylated tyrosine at the
YHPM site inMUC1CT (anti-pYHPM) was developed and uti-
lized to evaluate the effect of HGF stimulation on MUC1CT
phosphorylation. The antibody has been described previously
(13). Nuclear and cytoplasmic extracts from HGF-stimulated
S2-013.MUC1F and HPAF2 cells were resolved on SDS-PAGE
followed by Western blotting with the anti-pYHPM antibody.
The results revealed a significant increase in phosphorylation of
tyrosine in the YHPM motif that was concordant with an
increased duration of HGF stimulation, mostly observed in the
nuclear fraction (Fig. 3, D and E).
Real time laser scanning confocal imaging was performed on
S2-013 cells stably transfected with C-terminally tagged EYFP
(S2-013.MUC1.CT-EYFP). The cells were serum-starved for
24 h and then stimulated withHGF (100 ng/ml) after two initial
scans to establish steady state localization under unstimulated
conditions. HGF stimulation significantly enhanced the
nuclear localization of MUC1CT from cytoplasmic and cell
surface locations within seconds tominutes of stimulation (Fig.
3F). By 15 min post-stimulation, there was significant turnover
of MUC1CT.
The effects of HGF stimulation on nuclear localization of
MUC1CTwere also evaluated by immunofluorescence analysis
with the CT2 mAb (raised against the MUC1CT) after
paraformaldehyde fixation of the serum-starved or HGF-stim-
ulated S2-013.MUC1 cells. HGF stimulation significantly
enhanced the nuclear localization of MUC1CT (Fig. 3G). Fur-
thermore,mutating a tyrosine in the YHPMmotif to phenylala-
nine (S2-013.MUC1.FHPM) significantly abrogated the effect
of HGF stimulation on nuclear localization of MUC1CT.
Responses to HGF Stimulation of Met Are Down-regulated by
MUC1—We evaluated the effect of MUC1 overexpression on
HGF stimulation of migration by in vitromotility and invasion
assays performed in Boyden chambers with S2-013.MUC1F
and S2-013.Neo.MUC1 expression has been shown to facilitate
steady state in vitromotility and invasion in pancreatic adeno-
carcinoma cells (27, 28), and this was confirmed by the data
presented in Fig. 4 (S2013.Neo cell migration is less than
S2013.MUC1 under unstimulated conditions). Similar results
were observed with the MUC1-transfected and control cancer
FIGURE 4. MUC1 abrogates HGF-stimulated motility and invasion. S2-013.Neo, S2-013.MUC1F, or S2-013.MUC1.FHPM cells were added to the upper
compartment of migration or invasion chamber in serum-free culture media. HGF-containing media were added to the lower chamber. After 24 h of incuba-
tion, cells in the upper chamber were removed, and cells that hadmigrated or invaded onto the lower surface of themembrane were stained and counted in
10 different fields of lightmicroscopy. Bars representmean S.E. ofmigrating (A) or invading cell number (B) from three independent experiments performed
in triplicate (*** indicatesp0.001and** indicatesp0.01). To study theactin cytoskeletonchanges, cellswere serum-starved for 24hor stimulatedwithHGF
for 2 h post-serum starvation. The actin cytoskeletonwas visualizedwith Alexa-488-conjugated phalloidin (green), and the nuclei were stainedwith propidium
iodide (red) and analyzed by laser scanning confocal microscopy (A). The horizontal size bars represent 20 m.
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cell lines MDA-MB-435.Neo and MDA-MB-435.MUC1 (data
not shown). There was an 16-fold increase in the number of
S2-013.Neo cells migrating to the other side of the filter in
response to HGF-containing medium, as compared with non-
stimulated controls. Themagnitude of this increase in response
to HGF stimulation was reduced by half (to 8-fold) for
S2-013.MUC1F cells (Fig. 4A). The differences in HGF-stimu-
latedmotility of S2-013.MUC1F and S2-013.Neo cells were sta-
tistically significant (p  0.0001). Similar results (although
smaller in scale) were obtained whenMDA-MB-435 cells were
evaluated in the same manner. Stimulation of MDA-MB-
435.Neo cells with HGF produced a 70% increase in motility,
but there was only a 35% increase in motility in MDA-MB-
435.MUC1 cells expressing MUC1 (data not shown, 4 inde-
pendent experiments with 3 replicates each). Evidence of dif-
ferences in motility between S2-013.MUC1F and S2-013.Neo
cells was also reflected in the lamellipodial structures observed
by Alexa488-Phalloidin staining, with and without HGF stimu-
lation (Fig. 4A). S2-013.Neo cells showed significantly more
lamellipodial structures during HGF stimulation, as compared
with S2-013.MUC1F cells. Similarly, results of Matrigel inva-
sion assays under HGF stimulation (Fig. 4B) revealed that
S2-013.Neo cells exhibited greater than 8-fold increases in in
vitro invasiveness as compared with S2-013.MUC1F cells,
which showedmodest increases of2.5-fold (p 0.0001). The
cancer cell line MDA-MB-435.neo showed a 4.5-fold increase
in invasiveness upon stimulation with HGF, which was
decreased slightly to a 4.0-fold increase in MDA-MB-
435.MUC1 cells expressing MUC1 (data not shown, 4 inde-
pendent experiments with 3 replicates each). S2-013.
MUC1.FHPM cells did not show significant abrogation of
HGF-induced invasiveness (Fig. 4B).
MUC1 Abrogates HGF-stimulated Transcriptional Acti-
vation of MMP1—HGF stimulation of Met has been impli-
cated in transcriptional activation of MMP1, leading to
enhanced invasiveness in different cancer cell types (29, 30).
We evaluated S2-013.MUC1F and S2-013.Neo cells for
MMP1 mRNA expression by semiquantitative reverse tran-
scription-PCR. MUC1 overexpressing cells showed no
increase in MMP1 mRNA expression under HGF stimula-
FIGURE 5.MUC1 abrogates HGF-stimulated activation of MMP1 expression. S2-013.MUC1F and S2-013.Neo cells were cultured to 60% confluence,
serum-starved for 24 h, and then stimulated with platelet-derived growth factor (PDGF) (50 ng/ml) or HGF (100 ng/ml) for 24 h or left unstimulated.
A, expression of MMP1 was determined by semiquantitative reverse transcription-PCR. The expression of -actin was determined as a control. MMP1
promoter-luciferase reporter activity was assayed in S2-013.MUC1F, S2-013.CT3, and S2-013.Neo cells (B) as well as Panc1.MUC1F, Panc1.CT3, and
Panc1.Neo cells (C) under HGF stimulation. Cells were cotransfected with 512hMMP1 luciferase reporter plasmid and Renilla luciferase plasmid
(control for transfection efficiency). Cells were subsequently stimulated with HGF (100 ng/ml) or left unstimulated for 24 h. Cells were harvested, and
proteins were assayed for dual luciferase activity. Three independent transfections were performed in triplicate, and the results are expressed as the
mean of relative light units normalized with Renilla luciferase activity  S.E. (*** indicates p  0.001).
Phosphorylation ofMUC1 byMet
OCTOBER 3, 2008•VOLUME 283•NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 26991
 
 
tion (Fig. 5A); however, MMP1 expression was enhanced in
response to HGF in S2-013.Neo cells. As a control, stimula-
tion with platelet-derived growth factor resulted in
increased MMP1 expression in both cell types. To confirm
these findings, we evaluated the activity of an MMP1 pro-
moter luciferase reporter plasmid system. The results of
these assays indicated significantly higher HGF-stimulated
activation of the reporter system in S2-013.Neo and
Panc1.Neo cells as compared with S2-013.MUC1F (Fig. 5B)
and Panc1.MUC1F cells (Fig. 5C), respectively. However,
expression of a truncated cytoplasmic tail construct of
MUC1 (S2-013.CT3 and Panc1.CT3) did not abrogate the
HGF-mediated increase in MMP1 expression. These results
indicated that MUC1CT down-regulated HGF-mediated
activation of MMP1 promoter activity.
MUC1 Abrogates HGF Stimulation-mediated Activation of
AP1 Transcription Factor Activity—We investigated the role
of different DNA elements in the regulation of MMP1
expression upon HGF stimulation by utilizing MMP1 pro-
moter-luciferase reporter constructs having mutations in
the first ETS region (ETS1), the AP1-binding region, and the
second ETS region (ETS2) (24). Assays with these promoter-
luciferase reporter constructs showed that mutating the ETS
regions significantly decreased luciferase reporter activity;
however, the mutated ETS luciferase reporters still showed a
2-fold increase in reporter activity upon stimulation with
HGF (Fig. 6, A and B). Constructs with mutations in the
AP1-binding region showed greatest decrease in the reporter
activity, and the effect of HGF stimulation was also totally
abrogated. This supports the hypothesis that the AP1 tran-
scription factor is involved in the HGF-stimulated regulation
of MMP1 promoter activity. Because MUC1 also abrogated
the effect of HGF stimulation, we evaluated the effect of
MUC1 on AP1-dependent transcriptional activity under
HGF stimulation by evaluating transcriptional activity with
an AP1-responsive promoter-luciferase reporter construct.
The S2-013.Neo cells showed a 4-fold increase in AP1-re-
sponsive luciferase reporter activity under HGF stimulation,
as compared with serum-starved conditions (Fig. 6C). How-
ever, the S2-013.MUC1F cells showed no significant increase
FIGURE 6.AP1 transcriptional activity is down-regulated byMUC1 and is crucial for HGF-mediated activation ofMMP1promoter activity. S2-013
(A) and Panc1 cells (B) were cotransfected with512hMMP1 luciferase reporter plasmid or the mutant reporter plasmids and Renilla luciferase plasmid.
The512hMMP1 luciferase reporter plasmids were either wild type (WT) or contained mutations in the first ETS region (ETS1), the AP1-binding region
(AP1), or the second ETS region (ETS2). Cells were subsequently stimulated with HGF (100 ng/ml) or left unstimulated for 24 h. Cells were harvested, and
proteins were assayed for dual luciferase activity. S2-013.MUC1F and S2-013.Neo cells were co-transfected with pAP1-luciferase reporter plasmid and
Renilla luciferase plasmid (C). Cells were subsequently stimulated with HGF (100 ng/ml) or left unstimulated for 24 h and analyzed for AP1-responsive
promoter activity. Three independent transfections were performed in triplicate, and the results are expressed as the mean of relative light units
normalized with Renilla luciferase activity  S.E. (*** indicates p  0.001, ** indicates p  0.01, and * indicates p  0.05).
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in AP1-responsive luciferase reporter activity under HGF
stimulation.
HGF Stimulation Facilitates Interaction of MUC1CT with
p53 and Activates p53 to Abrogate MMP1 Expression—Previ-
ous studies have reported interactions betweenMUC1 and p53
in the region of MUC1CT containing theMet phosphorylation
site (33). Because it has also been reported that p53 can block
the interaction of AP1 transcription factor with basal transcrip-
tion machinery to abrogate MMP1 expression, we wanted to
determine whetherMet-phosphorylatedMUC1 contributed to
effects of p53 onMMP1 promoter activity (34–36). We inves-
tigated this possibility by performing co-immunoprecipitation
of MUC1 and p53 from serum-starved and HGF-stimulated
S2-013.MUC1F cells. Immunoprecipitations with the CT2
antibody against the MUC1CT were resolved on SDS-PAGE
and subjected to immunoblotting with an anti-p53 pAb. HGF
stimulation of S2-013.MUC1F cells significantly enhanced the
interaction of MUC1CT with p53 (Fig. 7A). Furthermore,
mutating a tyrosine in the YHPMmotif to phenylalanine signif-
icantly abrogated this association, whilemutating the same res-
idue to glutamate (providing a phosphorylation-mimicking
negative charge) significantly enhanced the interaction of
MUC1 with p53 (Fig. 7B).
Having established the effect of HGF stimulation on interac-
tion of MUC1CT with p53, we wanted to determine whether
activation of p53 affected the MUC1-mediated abrogation of
MMP1 promoter activation. For this purpose, we stimulated
S2-013.MUC1F and S2-013.Neo cells withHGF in the presence
or absence of 50 M etoposide, an activator of p53 (37, 38).
Etoposide treatment significantly decreasedMMP1 expression
in the presence or absence of HGF stimulation of
S2-013.MUC1F cells (Fig. 7C). However, etoposide treatment
enhanced MMP1 promoter activity in S2-013.Neo cells, sug-
gesting that MUC1 overexpression augmented the inhibitory
activity of p53 on theMMP1 promoter in pancreatic adenocar-
cinoma cells.
MUC1CT Physically Occupies the MMP1 Promoter and Pro-
moter Occupancy Is Enhanced by HGF Stimulation—Given the
evidence presented here that theMUC1CTwas acting as a tran-
scriptional co-regulator, and has been shown to physically
occupy different promoter elements (33), we sought to deter-
mine whether MUC1CT was present in transcriptional com-
plexes at theMMP1 promoter, and if promoter occupancy was
regulated by HGF stimulation. A quantitative ChIP assay dem-
onstrated greater than 3-fold increases in MMP1 promoter
(pMMP1) occupancy by MUC1CT at the AP1-binding site fol-
lowing HGF stimulation as compared with serum-starved con-
ditions at 24 h (Fig. 7, D and E). Control IgG ChIP assays
showed no enrichment at the pMMP1 site. As an additional
control, we tested for enrichment of other unrelated elements
(GUSB promoter) when immunoprecipitated with CT2 from
serum-starved andHGF-stimulated cells, andMMP1 promoter
occupancy was normalized to GUSB promoter occupancy.
Also, no enrichmentwas detected at sites 1.5 kb upstreamof the
MUC1-binding region in theMMP1 promoter.
DISCUSSION
In this study, we identifiedMet as a novel interaction partner
and kinase for the MUC1CT. We demonstrated that MUC1
associates with Met in pancreatic tumor cells, and under con-
ditions of HGF stimulation MUC1 promotes endocytosis and
increased turnover of Met. Overexpression of MUC1 down-
regulated HGF stimulation-induced interaction of Met with
conventional downstream signal transducers and inhibited
FIGURE 7. Phosphorylation ofMUC1CT byMet enhances interaction with p53 and activation of p53 further down-regulatesMMP1 expression in the
presenceofMUC1. Serum-starved orHGF-stimulated S2-013.MUC1F cell extractswere co-immunoprecipitated (IP) with CT2mAbor isotype control antibody
and immunoblotted (IB) for p53 (A). S2-013.MUC1F, S2-013.MUC1.FHPM, and S2-013.MUC1.EHPM cells were also analyzed for the effect of phosphorylation
abrogating or mimicking mutations at tyrosine in the YHPM motif for their effect on interaction of MUC1 with p53 by co-immunoprecipitations (B). Serum-
starved or HGF-stimulated S2-013.MUC1F and S2-013.Neo cells were co-transfected with MMP1 promoter luciferase reporter constructs, and the promoter
activity was assayed in the presence or absence of etoposide treatment (10 M), to activate p53 (C) (* indicates p 0.05). Promoter occupancy of MUC1CT at
MMP1 promoter (pMMP1) under serum-starved and HGF-stimulated conditions was determined by performing ChIP assay on S2-013.MUC1 cells by utilizing
CT2 mAb or control IgG followed by real time PCR with pMMP1 primers, primers to the 1.5-kb region upstream of pMMP1 or GUSB primers. The amount of
pMMP1 immunoprecipitatedwithCT2wasnormalizedwith input andplotted as relative amounts of pMMP1 immunoprecipitatedwithCT2 comparedwith the
serum-starved conditions  S.E. (D). The PCR products were also visualized on a gel to determine the specificity of amplification after 40 cycles (E). The
experiment was performed in triplicate.
Phosphorylation ofMUC1 byMet
OCTOBER 3, 2008•VOLUME 283•NUMBER 40 JOURNAL OF BIOLOGICAL CHEMISTRY 26993
 
 
subsequent biological responses (motility and invasion). The
results clearly demonstrate that MUC1 is a regulator of Met
signaling in pancreatic adenocarcinoma cells.
Our results demonstrate that under serum-starved condi-
tions, whichmight simulate the effects of autocrine growth fac-
tor stimulation, MUC1-overexpressing cells have higher Met
signaling activity, as indicated by greater steady state interac-
tion with Gab1. These findings suggest that MUC1 facilitates
activation of Met in an environment that contains low levels of
HGF.Hence,MUC1 expressionmay confer on tumors a greater
propensity tometastasizewhen present in lowHGF tissue envi-
ronments. Conversely, MUC1 also down-regulated HGF-stim-
ulated activation of motility and invasion under conditions of
high HGF concentrations. Additional indirect evidence of this
biological effect was provided by our observation of down-reg-
ulation of HGF-mediated transcriptional activation of MMP1
in MUC1-overexpressing cells, which is discussed further
below. MMP1 is a well known target of Met activation and is a
regulator of metastasis by virtue of its extracellular matrix
degrading activity (32).
Previously, theC terminus of another transmembranemucin
expressed in the kidney, MUC20, was shown to associate with
Met and impair downstream signaling through the Grb2-Ras-
ERK1/2 pathway by blocking Grb2 recruitment to HGF-acti-
vated Met (39), without affecting signaling through Gab1/
phosphatidylinositol 3-kinase pathways. That these effects
were distinct from the pathways affected by interactions
between MUC1 and Met suggests that interactions between
cell surface mucins andMet are important and specific mod-
ulators of Met signaling activity. The tissue-specific patterns
of expression of different transmembrane mucins may thus
confer tissue-specific effects on Met signaling, both consti-
tutive and HGF-stimulated.
High expression of HGF and Met has been reported in both
early and late neoplastic ductal lesions of pancreatic cancer,
suggesting that this may comprise an autocrine regulatory cir-
cuit (40). However, fully neoplastic and invasive cells lack the
expression ofMet, which has been further correlated with poor
survival of cancer patients (40). It has been proposed for pan-
creatic cancer that up-regulation of Met receptor expression
andHGF-Met interactionmay have a crucial role in early stages
of neoplasia, although subsequent loss may promote more
aggressive behavior of tumor cells (40). MUC1-facilitated turn-
over of Met might reflect a similar biological phenomenon.
Also, it is expected that activation of Met, which is well known
to induce cell scattering,might be crucial during early phases of
metastatic spread of cancer cells and also contribute to early
stages of survival at different metastatic sites. However, once
cells are established at different locations, theymay turn offMet
to facilitate growth of a compact tumormass. MUC1-mediated
endocytosis (which we demonstrate in this report) might
down-regulate levels ofMet at the cell surface under conditions
of high HGF concentrations.
We demonstrated that Met is a kinase for MUC1CT, phos-
phorylating the latter at a tyrosine in the YHPMmotif. What is
the biological role of Met-mediated phosphorylation of
MUC1CT? Previous studies have indicated that tyrosine phos-
phorylation of MUC1CT is crucial for its nuclear localization
(8, 13). Real time confocal imaging ofMUC1-GFP constructs as
well as confocal imaging of fixed cells post-HGF stimulation
were consistent with the hypothesis that there are pools of cell
surface and intracellular (perhaps pre-endocytic or endocytic)
MUC1CT under steady state conditions, and that stimulation
withHGF induced nuclear localization ofMUC1CT from these
compartmentswithin seconds tominutes of stimulation.West-
ern blotting analysis of nuclear and cytoplasmic extracts of
S2-013.MUC1F cells indicated that a majority of the YHPM
phosphorylated fraction of MUC1CT is rapidly transported to
and resident in the nucleus. It should be noted that although the
in vitro studies prove that there is a direct kinase-substrate rela-
tionship between Met and MUC1, the phosphorylation of
MUC1 detected upon HGF stimulation in cells could also be
indirect and mediated through other kinases that are activated
downstream of Met.
In this study, we also investigated the functional role of
nuclear localization of MUC1CT post-HGF stimulation. We
showed that HGF stimulation facilitated interaction of
MUC1CT with p53, and phosphorylation of MUC1CT at tyro-
sine in the YHPM motif significantly enhanced its interaction
with p53. The p53 protein has been reported previously to
down-regulate MMP1 promoter activity by abrogating the
interaction of AP1 transcription factor with basal transcrip-
tional machinery (34–36). Our studies show thatMUC1 blocks
the HGF-mediated activation of AP1 transcriptional activity.
Moreover, overexpression of MUC1 abrogates MMP1 pro-
moter activity in a manner that is regulated by the AP1 tran-
scription factor, which is further suppressed by etoposide-me-
diated activation of p53. However, control cells lacking MUC1
expression do not show p53-mediated inhibitory effects on
MMP1 promoter activity, suggesting that interaction of p53
with MUC1CT facilitates the inhibitory effect of p53 on the
MMP1 promoter.
The results presented here provide the first evidence that
MUC1CT physically occupies the MMP1 promoter. The
presence of MUC1CT in the transcriptional complex at the
MMP1 promoter, which is further facilitated by HGF stim-
ulation and occurs in the region of the promoter bound by
p53 and AP1, significantly inhibited MMP1 promoter activ-
ity. Hence these studies suggest a transcriptional co-repres-
sor role for MUC1CT.
Overall, this study provides insight into a mechanism by
which MUC1, a cell surface associated mucin, engages in mor-
phogenetic signal transduction, by directly influencing the
steady state levels of protein expression of an associated recep-
tor tyrosine kinase (Met), its downstream signaling, and by
enacting a unique signal transduction pathway in which phos-
phorylated MUC1CT associates with p53 and modulates tran-
scription of the MMP1 gene. Our findings demonstrate that
signaling in response to HGF stimulation is influenced at mul-
tiple levels by interactions between Met and MUC1, including
influences on conventional Met signaling, and the induction of
a specific signaling pathway that involves the phosphorylated
MUC1CT. Given that MUC1 and Met are overexpressed in
pancreatic adenocarcinoma, further studies of MUC1 and Met
signaling should provide additional insights into the molecular
Phosphorylation ofMUC1 byMet
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mechanisms that regulate invasion andmetastasis of pancreatic
cancer.
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Supplemental Figure 1: Silver stained gel image. MUC1CT was immunoprecipitated from S2-013.MUC1F cells by utilizing control IgG
or CT2 mAb. The immunoprecipitants were resolved on tris glycine SDS-PAGE and silver stained. The indicated band was
 identified as Met receptor tyrosine kinase.
